No definition available.
Sequelae of inflammatory diseases of the central nervous system
G6_NEUROINFSEQ
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
124 |
4. Check minimum number of eventsNone |
124 |
5. Include endpointsNone |
124 |
6. Filter based on genotype QC (FinnGen only) |
112 |
Control definitions (FinnGen only)
- Control exclude
- G6_NEUINFL
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G00-G09
- Name in latin
- Sequelae morborum inflammatoriorum systematis nervosi centralis
Similar endpoints
↥List of similar endpoints to
Sequelae of inflammatory diseases of the central nervous system
based on the number of shared cases.
Similar with more cases:
- Inflammatory diseases of the central nervous system
- Neurological diseases
- Neurological diseases, wide definition
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1421 | 653 | 746 |
| Only index persons | 880 | 437 | 443 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 43.55 | 45.47 | 41.45 |
| Only index persons | 36.06 | 39.65 | 32.52 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 112 | 55 | 57 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 39.34 | 32.63 | 45.80 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 117
- Matched controls
- 1170
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G09
ICD-10 Finland
Sequelae of inflammatory diseases of central nervous system
+∞
80.9
68
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
11.6
24.0
28
31
32400
ICD-8 Finland
Late effects of intracranial abscess or pyogenic infection, Hydrocephalus acquisitus
+∞
22.6
21
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.9
10.8
18
15
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.3
10.6
24
54
G06.0
ICD-10 Finland
Intracranial abscess and granuloma
+∞
10.6
10
*
N03AF01
ATC
carbamazepine; oral, rectal
6.1
10.0
19
36
A86
ICD-10 Finland
Unspecified viral encephalitis
60.1
9.8
11
*
XA800
NOMESCO Finland
Neuropsychological investigation
8.3
9.6
21
30
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
+∞
8.4
8
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.6
8.0
33
116
N03AE01
ATC
clonazepam; systemic
8.6
7.7
16
21
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.4
7.6
21
55
G40.9
ICD-10 Finland
Epilepsy, unspecified
9.4
7.6
15
18
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
12.0
7.5
13
12
32401
ICD-8 Finland
Late effects of intracranial abscess or pyogenic infection, Status postencephaliticus
+∞
7.4
7
*
AA1AD
NOMESCO Finland
CT of head and brain
3.0
7.3
47
215
TAB00
NOMESCO Finland
Lumbar puncture
6.3
7.3
19
35
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.5
7.3
30
105
N03AF02
ATC
oxcarbazepine; oral
9.8
7.3
14
16
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
12.0
7.0
12
11
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
6.7
6.9
17
29
R51.80
ICD-10 Finland
Headache
3.1
6.7
35
141
R42
ICD-10 Finland
Dizziness and giddiness
3.0
6.7
38
161
N99
ICPC
Neurological disease other
28.4
6.3
8
*
G04.8
ICD-10 Finland
Other encephalitis, myelitis and encephalomyelitis
+∞
6.3
6
*
N03AX18
ATC
lacosamide; systemic
+∞
6.3
6
*
2133
FHL
Suntin revisio
+∞
6.3
6
*
G03.9
ICD-10 Finland
Meningitis, unspecified
+∞
6.3
6
*
32408
ICD-8 Finland
Late effects of intracranial abscess or pyogenic infection, Alia definitae
+∞
6.3
6
*
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.9
6.2
20
59
N18
ICPC
Paralysis/weakness
16.1
6.0
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
11
8
15.00
7.04
1.2
1.0
—
—
—
0
0
10
6
18.03
6.87
2.9
1.2
4.45
1.66
mmol/l
—
10
6
10
10
10.80
5.65
1.2
1.0
—
—
—
0
0
8
5
17.01
5.49
1.3
1.0
—
—
—
0
0
9
8
12.05
5.39
1.2
1.0
—
—
—
0
0
26
107
2.84
4.71
3.8
8.4
0.88
0.87
mmol/l
0.00
18
94
7
7
10.53
4.06
1.1
1.0
—
—
—
0
0
31
155
2.36
3.75
1.7
1.7
1379.38
1212.29
nmol/l
0.57
26
119
5
5
10.36
3.00
1.2
3.6
—
—
—
0
0
7
13
5.65
2.91
3.0
2.7
1.18
1.21
mmol/l
—
7
13
7
13
5.65
2.91
3.0
2.7
105.86
107.77
mmol/l
—
7
13
7
13
5.65
2.91
1.1
1.2
—
—
—
0
0
5
6
8.63
2.77
1.4
2.7
15.00
7.00
%
—
5
6
5
6
8.63
2.77
1.0
1.2
—
—
—
0
0
17
74
2.52
2.73
1.7
1.4
—
—
—
0
0
67
496
1.82
2.56
10.1
7.5
1.20
1.22
mmol/l
0.64
60
437
77
596
1.85
2.53
14.6
10.6
4.62
4.26
e9/l
0.53
69
529
8
22
3.82
2.41
2.3
1.2
—
—
—
0
0
29
168
1.97
2.36
2.0
1.9
—
—
—
0
0
8
23
3.65
2.31
1.8
1.2
—
—
—
0
0
23
124
2.06
2.27
1.9
1.7
—
—
—
0
0
43
288
1.78
2.23
3.8
3.9
0.00
0.00
estimate
-0.00
17
99
11
42
2.78
2.21
2.3
2.6
—
—
—
0
0
9
31
3.06
2.12
1.4
1.3
—
—
—
0
0
60
449
1.69
2.06
7.3
6.1
1.20
1.22
mmol/l
1.14
55
423
8
26
3.22
2.05
1.3
1.3
—
—
—
0
0
21
114
2.03
2.03
2.0
1.8
—
—
—
0
0
69
541
1.67
1.95
5.2
3.7
0.00
0.00
estimate
-0.00
18
105
69
548
1.63
1.80
5.4
3.8
0.00
14.37
estimate
0.50
18
113
11
48
2.43
1.76
3.4
2.6
3.43
1.26
%
1.55
11
48
18
98
1.99
1.73
8.2
7.7
—
—
—
0
0
5
13
3.97
1.73
1.6
1.5
—
—
—
0
0
54
407
1.61
1.72
5.4
3.7
0.15
0.00
estimate
0.47
13
91
53
400
1.59
1.67
4.1
3.7
26.94
46.99
ng/l
0.80
43
279
30
196
1.71
1.65
2.7
2.7
2.44
2.47
mmol/l
0.46
25
172
16
85
2.02
1.64
3.1
2.6
0.20
0.23
g/l
0.54
16
80
25
155
1.78
1.64
3.0
2.9
1.78
3.28
e6/l
0.60
14
66
68
554
1.54
1.47
5.4
3.8
0.00
0.00
estimate
-0.00
17
103
14
74
2.01
1.46
4.1
8.3
1.69
1.33
mmol/l
0.47
14
74
6
22
2.82
1.45
7.7
1.8
—
—
—
0
0
6
22
2.82
1.45
1.0
1.1
—
0.72
—
0
5
0
41
0.00
1.34
0.0
1.4
—
229.98
—
0
21
9
43
2.18
1.33
1.4
2.2
—
—
—
0
0
26
173
1.65
1.33
3.0
2.7
1.01
0.94
e6/l
0.06
15
84
26
173
1.65
1.33
2.8
2.5
12.25
13.84
umol/l
0.29
26
161
58
464
1.50
1.33
3.7
2.6
—
—
estimate
—
0
0
42
314
1.53
1.32
3.4
3.2
1070.71
1104.38
ng/l
0.02
35
263
18
108
1.79
1.31
2.9
1.9
287.78
391.55
nmol/l
2.11
18
99
5
18
2.85
1.30
1.4
1.2
—
—
—
0
0
17
101
1.80
1.28
3.8
2.8
12.34
14.63
nmol/l
0.73
17
96
5
19
2.70
1.23
1.0
1.7
—
—
—
0
0
5
19
2.70
1.23
1.0
1.7
—
—
—
0
0
7
31
2.34
1.12
1.9
1.4
—
—
—
0
0
5
21
2.44
1.10
1.2
1.9
—
—
—
0
0
0
30
0.00
0.99
0.0
1.3
—
—
—
0
0
51
419
1.39
0.93
2.2
2.2
100.01
98.81
pmol/l
0.06
26
211
10
56
1.86
0.91
1.6
1.9
—
—
—
0
0
6
30
2.05
0.88
1.7
4.5
0.00
0.00
g/l
—
6
30
14
89
1.65
0.86
2.1
2.3
0.17
0.18
e6/l
0.02
14
84
93
995
0.68
0.83
5.4
5.8
2.71
2.74
mmol/l
0.12
88
937
87
940
0.71
0.80
4.2
4.3
1.41
1.30
mmol/l
0.61
82
881
8
48
1.71
0.80
1.8
2.2
39.63
35.60
nmol/l
—
8
48
22
160
1.46
0.77
3.0
2.5
2.44
2.32
g/l
0.48
22
143
5
23
2.22
0.77
1.2
1.9
—
—
—
0
0
9
55
1.69
0.75
1.2
1.5
—
—
—
0
0
7
39
1.84
0.74
1.7
2.1
—
—
—
0
0
5
25
2.04
0.73
1.2
1.8
—
—
—
0
0
12
77
1.62
0.72
10.6
3.9
1.23
1.22
mmol/l
0.27
12
70
5
27
1.89
0.69
1.4
1.4
—
—
—
0
0
5
28
1.82
0.67
6.2
2.7
127.60
124.82
g/l
—
5
17
20
148
1.42
0.65
1.6
1.8
1.37
1.45
%
0.12
20
128
37
305
1.31
0.63
5.8
3.2
0.00
0.00
estimate
-0.00
12
89
5
30
1.70
0.62
1.2
1.7
—
—
—
0
0
8
52
1.58
0.61
1.4
1.3
—
—
—
0
0
8
54
1.52
0.58
1.5
1.7
—
—
—
0
0
6
38
1.61
0.55
7.5
2.0
—
—
—
0
0
35
293
1.28
0.53
4.8
3.0
0.16
0.31
e6/l
0.95
27
205
44
379
1.26
0.53
3.4
2.9
30.07
30.97
u/l
0.10
44
360
42
364
1.24
0.47
3.1
3.5
2.36
2.35
mmol/l
0.15
37
335
35
297
1.25
0.47
2.0
1.7
22.16
21.52
nmol/l
0.07
35
249
8
55
1.49
0.44
6.4
8.2
23.84
24.71
mmol/l
—
8
55
103
988
1.36
0.43
30.6
15.6
22.50
22.67
mg/l
0.02
97
828
5
34
1.49
0.41
1.2
1.9
—
—
—
0
0
5
34
1.49
0.41
1.2
1.9
—
—
—
0
0
10
136
0.71
0.40
2.2
2.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.9
—
2.33
—
0
18
29
246
1.24
0.39
4.4
3.7
1.02
1.02
kg/l
0.67
15
161
9
124
0.70
0.37
1.9
1.9
—
—
—
0
0
28
239
1.23
0.36
3.3
2.2
—
—
—
0
0
15
186
0.78
0.34
2.5
2.7
0.39
0.77
ug/l
—
9
106
5
39
1.29
0.23
1.6
1.3
—
12.47
—
0
8
29
260
1.15
0.22
1.5
1.3
2.38
0.98
u/ml
—
8
73
0
11
0.00
0.21
0.0
1.4
—
4.62
—
0
5
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
218.30
—
0
10
0
10
0.00
0.21
0.0
1.5
—
12.90
—
0
10
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
253.89
—
0
12
17
196
0.84
0.20
2.2
1.6
—
—
—
0
0
6
49
1.24
0.20
3.7
2.7
23.37
24.56
mmol/l
—
6
49
24
214
1.15
0.19
5.8
3.0
30.00
98.04
ng/l
0.97
18
161
13
153
0.83
0.19
2.0
1.4
—
—
—
0
0
18
205
0.86
0.19
1.6
1.3
1.25
7.28
u/ml
—
8
74
22
246
0.87
0.18
3.3
4.3
16.97
22.90
%
—
7
103
80
827
0.90
0.17
34.6
19.9
13.98
13.64
%
1.37
80
821
15
131
1.17
0.15
11.3
5.5
0.94
1.00
mmol/l
0.48
15
121
64
660
0.93
0.10
3.0
3.2
—
—
—
0
0
7
81
0.86
0.07
1.0
1.5
—
—
—
0
0
9
88
1.02
0.07
5.4
3.3
—
—
—
0
0
31
319
0.96
0.02
4.3
3.8
5.00
11.51
mg/mmol
0.84
22
192
23
233
0.98
0.00
1.5
1.3
12.56
30.30
iu/ml
—
8
69
92
917
1.02
0.00
6.3
5.4
1.85
1.83
mu/l
0.05
87
852
0
5
0.00
0.00
0.0
1.6
—
58.70
—
0
5
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
5.4
—
53.40
—
0
5
0
5
0.00
0.00
0.0
1.6
—
13.60
—
0
5
0
9
0.00
0.00
0.0
1.2
—
9.11
—
0
9
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.8
—
4.74
—
0
6
5
58
0.86
-0.00
1.2
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
9.47
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.8
—
10.20
—
0
6
5
55
0.91
-0.00
1.0
1.3
—
—
—
0
0
7
72
0.97
-0.00
4.1
2.0
466.86
168.78
ng/l
—
7
64
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
59
1.02
-0.00
6.5
2.7
2.38
1.20
mmol/l
—
6
45
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_NEUROINFSEQ and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_NEUROINFSEQ | 2.449 [1.58, 3.79] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.263 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 211 females with G6_NEUROINFSEQ died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have G6_NEUROINFSEQ.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.273% | No data |
| 5 | 1.534% | No data |
| 10 | 3.802% | No data |
| 15 | 6.743% | No data |
| 20 | 11.591% | No data |
Relationships between endpoints
↥Index endpoint: G6_NEUROINFSEQ – Sequelae of inflammatory diseases of the central nervous system
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data